HowardR.TerebeloDO

Oncology • Ann Arbor, MI

Physician

Join to view full profile

Dr. Terebelo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Terebelo's full profile

Already have an account?

Office
1500 E Medical Center Dr
Ann Arbor, MI 48109
Phone+1 734-936-4000

Fax+1 248-552-0286

Summary

Dr. Howard Terebelo is an oncologist in Southfield, MI and is affiliated with multiple hospitals in the area, including McLaren Oakland, Ascension of Providence Hospital, Southfield Campus, Michigan Medicine, St. Joseph Mercy Oakland, Ascension St. John Hospital, and John D. Dingell Veterans Affairs Medical Center. He received his medical degree from Des Moines University College of Osteopathic Medicine and has been in practice 43 years. He is experienced in general / benign hematology and anemia.

Education & Training

National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1978 - 1981
National Capital ConsortiumResidency, Internal Medicine, 1975 - 1977
National Capital ConsortiumInternship, Transitional Year, 1974 - 1975
Des Moines University College of Osteopathic MedicineClass of 1974

Certifications & Licensure

MI State License 1987 - 2027
IL State License 1983 - 1987
IN State License 1984 - 1987
MD State License 1979 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome Start of enrollment: 1997 Aug 01
Unknown status
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer Start of enrollment: 2004 Nov 01
Unknown status
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2008 Dec 01
Active, not recruiting
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Start of enrollment: 2008 Dec 01
Completed
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris
Blood Advances. 2024-12-10
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
Sikander Ailawadhi, Hans C Lee, James Omel, Kathleen Toomey, James W Hardin
Blood Cancer Journal. 2024-11-11
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectMM Registry.
Howard R Terebelo, James Omel, Lynne I Wagner, James W Hardin, Robert M Rifkin
Clinical Lymphoma, Myeloma & Leukemia. 2024-11-06

Professional Memberships

American Society of Clinical Oncology - ASCO
Member